FLOQUET , Anne

Last name: FLOQUET

First name: Anne

January 2017 (v1)

Journal article

Metadata-only

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial

Rouzier, Roman Gouy, Sébastien Selle, Frédéric

To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma.

Uploaded on: February 28, 2023
October 2022 (v1)

Journal article

Metadata-only

Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort

Thomas, Quentin Dominique Boussere, Amal Classe, Jean-Marc

Objective. Interval debulking surgery is recommended after 3–4 cycles (standard IDS) of neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC) not able to received upfront complete debulking surgery. However, real world practices frequently report performing IDS after ≥5 NAC cycles (delayed IDS). The aim of this work was to...

Uploaded on: June 24, 2023
September 20, 2021 (v1)

Journal article

Metadata-only

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Berton, Dominique Floquet, Anne Lescaut, Willy

Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the French real-world setting.Patients and...

Uploaded on: December 4, 2022

FLOQUET , Anne

Recent uploads